Status unknownNCT01716884Updated Oct 30, 2012

China STEMI-PCI Program

An observational study in ST Segment Elevation Myocardial Infarction, sponsored by Peking University First Hospital. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2012-10-30.

Sponsored by Peking University First Hospital · Observational

The sponsor has not verified this record recently (last verified Oct 2012), so the status shown — last known as Recruiting — may be out of date.

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 4,000
Sex: All

Study summary

Registration
Performing in three stages
Major aim: Much more and standard reperfusion therapy in STEMI patients

Conditions studied

ST Segment Elevation Myocardial Infarction

Browse trials for

Keywords

STEMI
reperfution
primary PCI

In context

Myocardial Infarction

2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 500 across 983 observational studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

Peking University First Hospital is the lead sponsor of 378 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

STEMI Patients enrolled and followed up 1 year

Inclusion criteria

Onset of STEMI within 12h
Onset of STEMI within 12-36h needing primary PCI

Exclusion criteria

Exclusion Criteria:

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 4,000 participants (estimated)

What researchers measure

Primary outcomes

The reperfusion ratio
Time frame: up to 1 day

Secondary outcomes

Door to Balloon time
Time frame: up to 1 day
BMS ratio
Time frame: up to 1 day
health economic evaluation
Time frame: up to 1 year

Study locations

1 of 1 sites recruiting

Division of Cardiology, Peking University First Hospital
Beijing, 100034, China
- Yong Huo, MD · Principal investigator
Recruiting

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Oct 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01716884
Lead sponsor: Peking University First Hospital
Collaborators: Abbott Medical Devices, Sanofi
Responsible party: Yong Huo (Director of cardiovascular department, Peking University First Hospital) — Principal investigator
First posted: Oct 30, 2012
Start date: Dec 2011
Primary completion: Dec 2015 (estimated)
Completion: Jun 2016 (estimated)
Last update: Oct 30, 2012

Study contacts

Yan Zhang, MD

Contact

drzhy1108@163.com

8610-83575180

Oversight

Data monitoring committee: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Myocardial Infarction→

Other studies from this sponsor

Peking University First Hospital

Start the discussion